Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Potentiation of the chemotherapeutic action of tegafur against solid adenocarcinoma 755 by combination with l-cystine

  • 19 Accesses

  • 3 Citations

Summary

The chemotherapeutic action of tegafur (FT) against adenocarcinoma 755 in mice was markedly potentiated by oral administration of l-cysteine and l-cystine without increasing its toxicity. In particular, the combination of FT at 200 mg/kg per day (maximum dose) and 1000 mg/kg per day of l-cystine markedly inhibited tumor growth. The dose ratio of l-cysteine or l-cystine to FT needs 5 by weight to potentiate the antitumor activity of FT. The antitumor activity of 5-fluorouracil (FU) was slightly, but not significantly, increased by l-cysteine.

The total concentration of FT in the plasma and the tumor when it was given in combination with l-cystine was significantly increased when compared with FT alone 1 h after oral administration. The FU level in the plasma after administration of the combination of FT and l-cystine was three times higher than that after FT alone, and the FU level in the tumor after treatment with the combination of FT and l-cystine was also higher (about 20%) than that after FT alone.

This significant increase in FT and FU levels in the plasma and the tumor may be related to the potentiation of the antitumor activity of FT by l-cystine.

This is a preview of subscription content, log in to check access.

References

  1. Au JL, Wu AT, Friedman MA, Sadée W (1979) Pharmacokinetics and metabolism of ftorafur (R,S-1-(tetrahydro-2-furanyl)-5-fluorouracil) in man. Cancer Treat Rep 63:343–350

  2. Benvenuto JA, Lu K, Hall SW, Benjamin RS, Loo TL (1978) Disposition and metabolism of 1-(tetrahydro-2-furanyl)-5-fluorouracil (ftorafur) in humans. Cancer Res 38:3867–3870

  3. Blokhina NG, Vozny EK, Garin AM (1972) Results of treatment of malignant tumors with ftorafur. Cancer 30:390–392

  4. Chaudhuri NK, Mukherjee KL, Heidelberger C (1958) Studies on fluorinated pyrimidines VII-The degradative pathway. Biochem Pharmacol 1:328–341

  5. Danysz A, Wierzba K, Wutkiewicz M, Pniewska A, Praglowski T, Burba-Anczewska I (1984) Influence of some sulfhydryl compounds on the antineoplastic effectiveness of 5-fluorouracil and 6-mercaptopurine. Arch Immunol Ther Exp 32:345–349

  6. Fujii S, Ikenaka K, Fukushima M, Shirasaka T (1978) Effect of uracil and its derivatives on antitumor activity of 5-fluorouracil and 1-(2-tetrahydrofuryl)-5-fluorouracil. Gann 69:763–772

  7. Fujii S, Kitano S, Ikenaka K, Fukushima M, Nakamura H, Maehara Y, Shirasaka T (1980) Effect of coadministration of thymine or thymidine on the antitumor activity of 1-(2-tetrahydrofuryl)-5-fluorouracil and 5-fluorouracil. Gann 71:100–106

  8. Hiller SA, Zhuk RA, Lidak M, Ziederman A (1968) Analogues of pyrimidine nucleosides in chemotherapy of cancer. Presented at the First All-Union Conference on the Chemotherapy of Malignant Tumors, Riga, October, 7–11 B-1.2/3

  9. Ichikawa Y, Yamano T (1967) Reconversion of detergent and sulfhydryl reagent produced P 420 to P-450 by polyols and glutathione. Biochim Biophys Acta 131:490–497

  10. Iigo M, Hoshi A, Nakamura A, Kuretani K (1978) Antitumor activity of 1-alkylcarbamoyl derivatives of 5-fluorouracil in a variety of mouse tumors. Cancer Chemother Pharmacol 1:203–208

  11. Iigo M, Nakamura A, Kuretani K, Hoshi A (1980) Metabolic fate of 1-hexylcarbamol-5-fluorouracil after oral administration in mice. Xenobiotica 10:847–854

  12. Kamataki T, Kitagawa H (1973) Effects of lipid peroxidation on activities of drug-metabolizing enzymes in liver microsomes of rats. Biochem Pharmacol 22:3199–3207

  13. Karev NI, Blokhina NG, Vozny EK, Pershin MP (1972) Experience with ftorafur treatment in breast cancer. Neoplasma 19:347–350

  14. Ohira S, Maezawa S, Watanabe K, Kitada K, Sato T (1975) Experimental approach to increase the effect of cancer chemotherapy in tumor-bearing rats pretreated with an inducer on microsomal drug metabolizing enzyme (Cytochrome P 450). Ninth In ternational Congress of Chemotherapy, London

  15. Remmer H, Merker HJ (1963) Drug-induced changes in the liver endoplasmic reticulum. Association with drug-metabolizing enzymes. Science 142:1657–1658

  16. Saito T, Maezawa S (1979) Increased antitumor activity following stimulated activation of anticancer drugs (Masked compounds). Cancer Chemother 6:245–256

  17. Toide H, Akiyoshi H, Minato Y, Okuda H, Fujii S (1977) Comparative studies on the metabolism of 1-(2-tetrahydrofuryl)-5-fluorouracil and 5-fluorouracil. Gann 68:553–560

  18. Valdivieso M, Bodey GP, Gotlieb JA, Freireich EJ (1976) Clinical evaluation of ftorafur (pyrimidine-deoxyribose N1-2′-furanidyl-5-fluorouracil). Cancer Res 36:1821–1824

  19. Wu AT, Au JL, Sadée W (1978) Hydroxylated metabolites of R,S-1-(tetrahydro-2-furanyl)-5-fluorouracil (ftorafur) in rats and rabbits. Cancer Res 38:210:214

  20. Yoshimura K, Iwauchi Y, Sugiyama S, Kuwamura T, Odaka Y, Satoh T, Kitagawa H (1982) Transport of l-cysteine and reduced glutathione through biological membrane. Res Commun Chem Pathol Pharmacol 37:171–176

Download references

Author information

Correspondence to M. Iigo.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Iigo, M., Hoshi, A. & Kitagawa, H. Potentiation of the chemotherapeutic action of tegafur against solid adenocarcinoma 755 by combination with l-cystine. J Cancer Res Clin Oncol 111, 187–190 (1986). https://doi.org/10.1007/BF00389232

Download citation

Key words

  • Tegafur
  • l-Cysteine
  • l-Cystine
  • Combination chemotherapy
  • Antitumor activity
  • Potentiation